Creation Of Linkage Map Falters, Posing Delay For Genome Project

Researchers, discouraged by mapping's drudgery, doubt that a 5-year plan to finish high-resolution image is now feasible. WASHINGTON--After three years of escalating expectations, rising financial support, and congressional accolades, the Human Genome Initiative has encountered its first major hurdle. A key element of the project has fallen several years behind schedule, in part because peer review panels at the National Institutes of Health decided that some incoming grant proposals on the to

Written byG. Christopher Anderson
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share


Researchers, discouraged by mapping's drudgery, doubt that a 5-year plan to finish high-resolution image is now feasible.
WASHINGTON--After three years of escalating expectations, rising financial support, and congressional accolades, the Human Genome Initiative has encountered its first major hurdle. A key element of the project has fallen several years behind schedule, in part because peer review panels at the National Institutes of Health decided that some incoming grant proposals on the topic were "boring." Of those scientists who were funded, many have diverted part of their research toward more tantalizing pursuits. The process of catching up may require a dramatic rethinking of many of the strategies of the 15-year, $3 billion project.

The immediate obstacle stems from a lack of progress on the so-called linkage map of the genome. The term refers to a list that links human traits and their associated genes to locations on the human DNA molecule. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies